If you have been reading about circadian rhythm and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
=== Toxin removal === Following diagnosis, rapid removal of excess leucine from the body reduces the impact of the disease on development. Some methods of toxin removal include Exchange transfusion, hemodialysis, or hemofiltration. Exchange transfusion is an option to consider because it decreases high BCAA levels without disrupting the plasma repeatedly, however after exchange the BCAA levels will increase with the tissue storage releasing BCAAs. Hemodialysis is a safe and effective way to reduce elevated BCAA levels while correcting electrolyte and acid-base imbalances in an infant. Hemodialysis can be started as soon as a diagnosis is made when it is combined with dietary feeds that maintain recommended calorie and amino acid intake.
The venous system is the system of veins in the systemic and pulmonary circulations that return blood to the heart. In the systemic circulation the return is of deoxygenated blood from the organs and tissues of the body, and in the pulmonary circulation the pulmonary veins return oxygenated blood from the lungs to the heart. Almost 70% of the blood in the body is in the veins, and almost 75% of this blood is in the small veins and venules. All of the systemic veins are tributaries of the largest veins, the superior and inferior vena cava, which empty the oxygen-depleted blood into the right atrium of the heart. The thin walls of the veins, and their greater internal diameters (lumens) enable them to hold a greater volume of blood, and this greater capacitance gives them the term of capacitance vessels. This characteristic also allows for the accommodation of pressure changes in the system. The whole of the venous system, bar the post-capillary venules is a large volume, low pressure system. The venous system is often asymmetric, and whilst the main veins hold a relatively constant position, unlike arteries, the precise location of veins varies among individuals.
=== Formulations === Available dosage forms include liquids, syrups, drops, elixirs, effervescent tablets, and powders for mixing with water, capsules, tablets including extended-release formulations, suppositories, compounding powder, and injections.
== Sierra Leone == Amadu Wurie - Educationist and politician, First Minister of Education and later Minister of Interior of Sierra Leone Sir Banja Tejan-Sie - Politician and lawyer. former vice president under SLPP (1953–1956), former chief justice and Governor-General of Sierra Leone Mohamed Juldeh Jalloh – Current vice president, Republic of Sierra Leone Abass Bundu – Current Speaker of Parliament Sierra Leone, former minister of foreign affairs, former Executive Secretary of the Economic Community of West African States Ibrahim Bundu - former majority leader of the Sierra Leone Parliament, Sierra Leone Abdulai Hamid Charm - former chief justice, Sierra Leone Umu Hawa Tejan-Jalloh – former chief justice, Diplomat, Sierra Leone Miatta Maria Samba - Sierra Leonian jurist and current judge at the International Criminal Court (ICC). Sulaiman Tejan-Jalloh – politician and Diplomat, former Minister of Transport and Communications and former ambassador to US, Sierra Leone Neneh Cherry (birth name Neneh Mariann Karlsson) – Singer-songwriter, rapper, occasional DJ and broadcaster, Sweden Titiyo (birth name Titiyo Yambalu Felicia Jah) – singer and songwriter, Sweden Alpha Timbo – Politician, educationist, lecturer and trade unionist. Minister of Primary and Secondary Education, former Minister of Labor and Industrialization, Sierra Leone Chernor Bah - Minister of Information and Civic Education Chernor Maju Bah – lawyer and politician.
Sources: en.wikipedia.org
==== Trump administration ==== On 6 February 2020, the director of the White House's Office of Science and Technology Policy requested the National Academies of Sciences, Engineering, and Medicine to convene a meeting of "experts, world class geneticists, coronavirus experts, and evolutionary biologists", to "assess what data, information and samples are needed to address the unknowns, in order to understand the evolutionary origins of COVID-19 and more effectively respond to both the outbreak and any resulting information". In April 2020, it was reported that the US intelligence community was investigating whether the virus came from an accidental leak from a Chinese lab. The hypothesis was one of several possibilities being pursued by the investigators. US Secretary of Defense Mark Esper said the results of the investigation were "inconclusive". By the end of April 2020, the Office of the Director of National Intelligence said the US intelligence community believed the coronavirus was not man-made or genetically modified. US officials criticised the "terms of reference" allowing Chinese scientists to do the first phase of preliminary research.
Positively charged ions were found to accumulate in the membrane. Multi-parametric surface plasmon resonance is one of the methods to study barrier properties of natural, modified or coated nanocellulose. The different antifouling, moisture, solvent, antimicrobial barrier formulation quality can be measured on the nanoscale. The adsorption kinetics as well as the degree of swelling can be measured in real-time and label-free.
== Sources == Bath, Richard (ed.) The Complete Book of Rugby (Seven Oaks Ltd, 1997 ISBN 978-1-86200-013-1) ed. Brown, Archie; Kaser, Michael & Smith, Gerald S. (ed.s) The Cambridge Encyclopedia of Russia and the former Soviet Union, (2nd Ed., Cambridge University Press, Cambridge, England 1994; ISBN 0-521-35593-1) Cotton, Fran (Ed.) The Book of Rugby Disasters & Bizarre Records. (Compiled by Chris Rhys, Century Publishing, London, 1984). ISBN 0-7126-0911-3 Griffiths, John. Rugby's Strangest Matches: Extraordinary but true stories from over a century of rugby (Past Times/Robson Books, England; ISBN 978-1-86105-354-1) Hopkins, John (ed) Rugby (1979 ISBN 0-304-30299-6) Laidlaw, Chris From Twickers with Love: Rugby's Universal Message in Hopkins, John (ed) Rugby (1979 ISBN 0-304-30299-6) Richards, Huw A Game for Hooligans: The History of Rugby Union (Mainstream Publishing, Edinburgh, 2007, ISBN 978-1-84596-255-5) Riordan, James Sport in Soviet Society — development of sport and physical education in Russia and the USSR (Cambridge University Press, Cambridge, England, 1977) Sorokin, A.A. (А. А.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.